Gb Sciences’ Novel Parkinson’s Disease Medication is Featured on Worldwide Business with kathy ireland®
Tune in this Sunday, Dec. 17, at 5:30 p.m. ET on the Fox Business Network to learn about Gb Sciences’ cannabinoid-based medicine for the treatment...
Gb Sciences’ First-in-Class Parkinson’s Disease Therapy Successfully Completes Dose Response Study at the University of Lethbridge
The Parkinson's disease market is expected to grow to $12.8 billion by 2028. Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and...
GB Sciences’ First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson’s Disease Has Been Issued in China
According to Statista, China has the second largest pharmaceutical market in the world and plant-based medicines are very well accepted, which makes China a potential...
Successful 2022 Milestones Support Value of Gb Sciences’ AI-Enabled Drug Discovery Platform
Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2023 and key developments from 2022LAS VEGAS, NV / ACCESSWIRE / March...
Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform
Gb Sciences' innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections. Gb Sciences, Inc. (OTCQB:GBLX),...
Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations
As mental health disorders increasingly impact global populations, Gb Sciences is developing psychotropic but non-psychedelic treatments for anxiety and depression that compete with the emerging...